标题
Vortioxetine: First Global Approval
作者
关键词
Major Depressive Disorder, Generalize Anxiety Disorder, Bupropion, Major Depressive Disorder, Duloxetine
出版物
DRUGS
Volume 74, Issue 1, Pages 135-145
出版商
Springer Nature
发表日期
2013-12-05
DOI
10.1007/s40265-013-0161-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats
- (2013) Yan Li et al. BEHAVIOURAL BRAIN RESEARCH
- Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant
- (2013) Grace Chen et al. CLINICAL DRUG INVESTIGATION
- A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition
- (2013) E L Theunissen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- P.2.b.011 Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder
- (2013) G. Filippov et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- P.1.g.014 Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms
- (2013) A. Pehrson et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- P.2.e.001 Single dose vortioxetine or ketamine but not fluoxetine increases expression of neuroplasticity related genes in the rat prefrontal cortex
- (2013) K.G. Du Jardin et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- P.2.e.003 Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine
- (2013) M.S. Riga et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- P.2.e.004 Vortioxetine (Lu AA21004) disinhibits pyramidal cell output and enhances theta rhythms and long-term plasticity in the hippocampus
- (2013) E. Dale et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- P.2.f.029 A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment
- (2013) L. Häggström et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects
- (2013) Per Stenkrona et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Multi-modality: a new approach for the treatment of major depressive disorder
- (2013) Elliott Richelson INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice
- (2013) Jean-Philippe Guilloux et al. NEUROPHARMACOLOGY
- Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats
- (2013) Arne Mørk et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
- (2012) David S. Baldwin et al. CURRENT MEDICAL RESEARCH AND OPINION
- A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder
- (2012) Atul R. Mahableshwarkar et al. CURRENT MEDICAL RESEARCH AND OPINION
- P.2.h.002 Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition
- (2012) N. Haddjeri et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States
- (2012) Anthony J. Rothschild et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial
- (2012) Leszek Bidzan et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- P.2.c.010 The multimodal antidepressant Lu AA21004: open-label long-term safety and tolerability study in major depressive disorder
- (2012) I. Florea et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—A rat microdialysis and electrophysiology study
- (2012) Alan L. Pehrson et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder
- (2012) David S. Baldwin et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder
- (2012) Cornelius Katona et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonism
- (2012) Cécile Bétry et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder
- (2012) Rakesh Jain et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder
- (2012) Neven Henigsberg et al. JOURNAL OF CLINICAL PSYCHIATRY
- A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder
- (2012) Jean-Philippe Boulenger et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects
- (2011) Johan Areberg et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Biosynthesis and Identification of an N-Oxide/N-Glucuronide Metabolite and First Synthesis of an N-O-Glucuronide Metabolite of Lu AA21004
- (2011) H. K. Uldam et al. DRUG METABOLISM AND DISPOSITION
- A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)
- (2011) David S. Baldwin et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
- (2011) Enric Alvarez et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
- (2011) Benny Bang-Andersen et al. JOURNAL OF MEDICINAL CHEMISTRY
- P.2.d.017 Pharmacological profile of Lu AA21004, a novel multi-target drug for the treatment of mood disorders
- (2009) A. Mørk et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started